Drug or intervention
Ribavirin Clinical Trials
Studies that test Ribavirin, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 7Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose…
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension
- Trial name
- POPS or POP02 (NCT04278404)
- Testing
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Duke University
HCV Infection ( Genotype 4) in CKD Patients
Treatment of CKD Patients With HCV
The goal of this clinical trial is to evaluate the optimal drug therapy of HCV in CKD Patients different stages with or without compensated cirrhosis.
- Trial name
- HCV/CKD (NCT07770984)
- Testing
- SOF+DCV, OBV/PTV/r) ± ribavirin (RBV)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Crimean-Congo Hemorrhagic Fever
UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF
CCHF has a wide geographical distribution with cases mainly occurring in Asia, the Middle East, South-Eastern Europe and Africa.
- Trial name
- UMIT-2 (NCT06860334)
- Testing
- Favipiravir, Ribavin, Optimised Standard of Care
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 378 people
- Sponsor
- Liverpool School of Tropical Medicine
Lassa Fever
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Lassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%.
- Trial name
- NCT06212336
- Testing
- Favipiravir, Ribavirin, Dexamethasone
- Where
- 4 sites in Liberia, Nigeria
- Volunteers
- 1,755 people
- Sponsor
- Irrua Specialist Teaching Hospital
Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human
Assessing Antiviral Treatments in Early Symptomatic RSV
This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated Respiratory Syncytial Virus (RSV), to determine in-vivo antiviral…
- Trial name
- ARSYNAL-FC (NCT06488300)
- Testing
- Ribavirin, Molnupiravir, Favipiravir
- Where
- 2 sites in Laos, Thailand
- Volunteers
- 1,000 people
- Sponsor
- University of Oxford
Lassa Fever
LAssa Fever Adjunct Treatment With DEXamethasone
Dexamethasone is a corticosteroid which can modulate inflammatory-mediated tissue damage associated with a wide range of infectious diseases.
- Trial name
- LADEX (NCT06222723)
- Testing
- Dexamethasone, Ribavirin
- Where
- Nigeria
- Volunteers
- 42 people
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
Chronic Hepatitis C, Medication Reaction
The Efficacy of Vosevi in Treating DAA-experienced Patients
Hepatitis C virus (HCV) infection remains a significant health problem in our country. The World Health Organization estimated that 71 million people worldwide had chronic HCV infection in 2015.
- Trial name
- NCT06180590
- Testing
- Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Completed, with results posted
All 427Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who relapsed after previous treatment.
- Trial name
- NCT01466192
- Testing
- MP-424 (generic name:Telaprevir), Ribavirin, Peginterferon alfa-2b
- Where
- Japan
- Volunteers
- 108 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.
- Trial name
- NCT00780910
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 109 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in treatment-naïve patients with (Genotype 1) hepatitis C.
- Trial name
- NCT00780416
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 189 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and RBV in patients with (Genotype 1) hepatitis C, who did not respond to previous treatment.
- Trial name
- NCT00781274
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who did not respond to previous treatment.
- Trial name
- NCT01468584
- Testing
- MP-424 (generic name:Telaprevir), Ribavirin, Peginterferon alfa-2b
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Tanabe Pharma Corporation